Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extension Study of Hetrombopag Olamine in Patients With Treatment-naive Severe Aplastic Anemia

NCT04961710 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT04961710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04961710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extension Study of Hetrombopag Olamine in Patients With Treatment-naive Severe Aplastic Anemia
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 19, 2019
Completion date
December 31, 2024
Enrollment
157 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

treatment-naive severe aplastic anemia